Rapid desensitization of humanized mice with anti-human Fc εRIα monoclonal antibodies

Although inoculating humanized mice with a large dose of anti-human Fc εRIα mAb induces anaphylaxis, administering the same mAb through a rapid desensitization approach safely removes nearly all IgE from mast cells and blocks IgE-mediated anaphylaxis.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research

Related Links:

We have prepared a case that highlights the relationship between a patient ’s emotional state and the potential for systemic allergic reactions including anaphylaxis in a heretofore stable patient receiving maintenance subcutaneous allergen immunotherapy (SCIT) for treatment of allergic rhinoconjunctivitis (ARC) and mild persistent asthma.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Challenging Clinical Cases Source Type: research
Hey guys, had a patient with sulfa/sulfonamides allergy who I dispensed Meloxicam. Pt states that sulfa is in meloxicam structure so she is having anaphylactic reaction due to taking Meloxicam 8 hours earlier I checked Lexicom/Clinical pharmacology, and I just cant find it being as contraindication... Of course, pt is threatening to go to a hospital/sue/etc... Am I overlooking it as a contraindication? Can you guys double check me?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Pharmacy Source Type: forums
This study aimed to identify the phenotype and immunologic findings in Korean children with barley allergy. METHODS: Forty-two participants with a history of ingesting barley who underwent serum specific immunoglobulin E to barley (barley-sIgE) assay at the Department of Pediatrics in Ajou Medical Center were enrolled through a retrospective analysis of medical records from March 2008 to February 2018. The demographic characteristics, symptoms, and immunologic parameters of the patients were assessed. RESULTS: Twenty subjects presented with clinical barley allergy (B-allergic group), and 22 were atopic controls w...
Source: J Korean Med Sci - Category: General Medicine Authors: Tags: J Korean Med Sci Source Type: research
AbstractPurpose of ReviewBiologic agents are new treatment options for chronic inflammatory diseases and cancers. As a result of their unique mechanism of action, they are more effective and less toxic treatment option and their clinical usage is increasing. While they are more commonly used, various adverse effects have been observed including life-threatening ones, including anaphylaxis. The aim of this review is to distinguish the anaphylaxis from other hypersensitivity reactions (HSR) and provide a management algorithm for the anaphylactic reactions induced by biological agents.Recent FindingsMany case reports and seri...
Source: Current Treatment Options in Allergy - Category: Allergy & Immunology Source Type: research
Publication date: Available online 16 January 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Matthew S. Krantz, Yiwei Liu, Elizabeth J. Phillips, Cosby A. Stone
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Conclusions. Although there was no increase in Api m10 sIgG4 levels after 1 year bVIT, we did not observe relevant differences in other outcomes between patients with predominant Api m1 or Api m10 sensitization. PMID: 31939631 [PubMed - as supplied by publisher]
Source: European Annals of Allergy and Clinical Immunology - Category: Allergy & Immunology Tags: Eur Ann Allergy Clin Immunol Source Type: research
Publication date: January 2020Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 8, Issue 1Author(s): Lisa M. Bartnikas, Scott H. Sicherer
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: January 2020Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 8, Issue 1Author(s): Ru-Xin Foong, Paul J. Turner, Adam T. Fox
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Abstract BACKGROUND: Peanut allergy (PA) affects ∼1.6 million US children. The current standard of care is strict avoidance and prompt reaction treatment. PA healthcare costs and healthcare resource utilization (HCRU) are poorly understood. OBJECTIVE: To estimate PA healthcare costs and HCRU using a nationally representative commercial payer database. METHODS: The IBM MarketScan ® Commercial Claims and Encounters Database was examined for PA diagnosis/reaction codes between January 2011 and October 2015 in patients ≤64 years, with age cohort-matched controls. Outcomes were measured 12 months b...
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Ann Allergy Asthma Immunol Source Type: research
AbstractPurpose of reviewThis paper aimed to summarize and review the known data on anaphylaxis and hypersensitivity reactions to vitamins.Recent FindingsVitamins A, C, D, and E seem to be extremely safe compounds, with few or no related case of anaphylaxis to them. Vitamin B1 is considered the most allergenic vitamin. Immediate reactions are unusual, but urticaria and anaphylaxis to thiamine intravenous administration have been described. Vitamin B12 hypersensitivity is also infrequent. Reactions occur mostly in patients receiving long-term supplementation. Desensitization is mandatory for patients with hypersensitivity t...
Source: Current Treatment Options in Allergy - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Anaphylactic Shock